Nemera and Zollner announce partnership for the development of electronic drug delivery devices
The new alliance will enable Nemera to offer enhanced connected drug delivery device solutions to customers and patients.
Nemera, world leader in design, development and manufacturing of drug delivery device solutions for the pharmaceutical, biotechnology and generic industries, today announced a partnership with Zollner Elektronik AG, one of the largest electronic manufacturing service providers in the world. Zollner is specialized in advanced mechatronics for Healthcare & Life Sciences, Railway Technology, Aerospace & Defense, Automotive Technology and many other sectors.
As a partner-of-choice, Zollner will support the design, development and manufacturing of electronic drug delivery systems for both, Nemera’s proprietary and customer owned products. This collaboration will begin with Nemera’s Symbioze, a high-volume wearable injection device. Nemera will entrust the development of the electronics & software part of Symbioze to Zollner.
“From the very beginning, Nemera has been a remarkable match for Zollner on both a technological and human level for mutually developing groundbreaking solutions toward a sustainable society. We are also very pleased to be able to support our partner at the largest international trade show for the pharmaceutical sector in Frankfurt, CPHI 2022, to further deepen our already very intensive partnership cooperation and jointly open up new growth markets”, says Erwin Stöckinger, Senior VP Business Division Electronics at Zollner.
Bernhard Rohn, Strategy and Marketing Vice President at Nemera said, “This strategic alliance strengthens both Nemera and Zollner’s offering combining drug delivery device and pharmaceutical industry knowledge with electronics development and manufacturing knowledge in the medical industry. Together, we’ll strive to develop the devices of tomorrow for improved patient care.”
At Nemera, we believe innovation truly thrives through collaboration that leverages knowledge for the advancement of science and benefit of the society. Our partnership with Zollner further strengthens our commitment to bringing superior value to customers and ultimately patients.
